Damora Therapeutics (DMRA) EBT (2019 - 2026)

Damora Therapeutics has reported EBT for 8 years, with the latest figure at -$27.7 million in Q1 2026.

• For the quarter ending Q1 2026, EBT fell 996.05% year-over-year to -$27.7 million; the trailing twelve-month figure through Mar 2026 stood at -$231.1 million (down 3152.27% YoY), and the FY2025 full-year result was -$205.9 million, down 1948.43% from the prior year.
• EBT for Q1 2026 stood at -$27.7 million, up from -$196.8 million in the prior quarter.
• The five-year high for EBT was $4.6 million in Q4 2024, with the low at -$196.8 million in Q4 2025.
• Historically, EBT has averaged -$20.2 million across 5 years, with a median of -$8.1 million in 2023.
• Annual changes were most pronounced in 2024 — EBT soared 170.98% — and 2025, when it tumbled 4382.68%.
• Damora Therapeutics' EBT stood at -$13.5 million in 2022, then surged by 52.13% to -$6.5 million in 2023, then soared by 170.98% to $4.6 million in 2024, then plunged by 4382.68% to -$196.8 million in 2025, then jumped by 85.91% to -$27.7 million in 2026.
• The last three EBT figures came in at -$27.7 million (Q1 2026), -$196.8 million (Q4 2025), and -$3.1 million (Q3 2025), per Business Quant data.